USC initiates trial of blood test for breast cancer
USC Norris Comprehensive Cancer Center has launched a Phase I clinical trial for a new liquid biopsy blood test designed to detect early-stage breast cancer. The test identifies rare cancer-associated cells and extracellular vesicles, aiming to provide a more effective screening alternative to traditional mammography.
Why it matters
Early detection of breast cancer significantly improves treatment outcomes, and this technology could reduce the anxiety and delays associated with inconclusive mammogram results.
The liquid biopsy is intended for use alongside regular screening to detect cellular and molecular markers of early-stage disease.
Study participants will provide two blood samples across a 12-month interval to compare against diagnostic findings..com. USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has initiated a Phase I clinical trial to determine whether a blood test can detect breast cancer earlier than standard mammograms.
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Specifically, it detects rare cancer-associated cells and tumour-associated large extracellular vesicles that enter the bloodstream during early disease development.
According to USC, over 300,000 women receive a breast cancer diagnosis in the US each year.
While mammography remains the standard screening method, abnormal results frequently require supplementary imaging, tissue biopsies, or follow-up examinations after six months.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in